Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

CLL International Prognostic Index (CLL-IPI)

The CLL-IPI integrates clinical stage with biological markers to stratify chronic lymphocytic leukaemia patients into four risk groups, developed from pooled data of 3,472 patients.

Purpose:
Predict overall survival in CLL and guide treatment timing decisions
Population:
Patients with chronic lymphocytic leukaemia (CLL)
Factors:
TP53 status (del(17p)/mutated), IGHV mutation status, β2-microglobulin, Clinical stage (Binet/Rai), Age
Reference:
International CLL-IPI Working Group, Lancet Oncology 2016
HomeCLL-IPI
Pin your most used calculators here by clicking the star in the dropdown.

CLL-IPI

Clinical Context & Background

The CLL-IPI combines genetic, biochemical, and clinical parameters to stratify survival in CLL patients. It is useful for counseling patients and designing clinical trials.
Primary Source EvidenceInternational CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
Formula Logic
Sum of weighted points: TP53(4), IGHV(2), B2M(2), Stage(1), Age(1).

Reference Data

Risk GroupScore5-Year Overall Survival
Low Risk0 - 193.2%
Intermediate Risk2 - 379.3%
High Risk4 - 663.3%
Very High Risk7 - 1023.3%

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)MIPI (Mantle Cell Lymphoma)IPS (Hodgkin Lymphoma)

Evidence-based oncology decision support. Verify with clinical guidelines.